Ocular Sebaceous Gland Carcinoma: an Update of the Literature

Overview

Journal Int Ophthalmol

Specialty Ophthalmology

Date 2018 Apr 27

PMID 29696467

Citations 21

Authors

Maria Vittoria Cicinelli

Swathi Kaliki

Affiliations

Soon will be listed here.

Abstract

Purpose: To review and summarize the newest update on ocular sebaceous gland carcinoma (SGC) focusing on diagnosis and treatment.

Methods: A PubMed search was carried out using the terms "Sebaceous Carcinoma", "Meibomian Gland Carcinoma", "Sebaceous Cell Carcinoma", and "Sebaceous Gland Carcinoma". All studies published in English up to October 2017 were included in this review.

Results: Globally, the overall incidence of SGC is increasing making it the third most common eyelid malignancy after basal cell carcinoma (BCC) and squamous cell carcinoma. The mainstay of treatment of ocular SGC is wide surgical resection under frozen section or Moh's micrographic surgery control followed by eyelid reconstruction. Based on histopathological features, SGC can be classified according to growth pattern, cell type, and cytoarchitecture. Based on the growth pattern, they can be classified as trabecular, lobular, papillary, and BCC-like. The cell type can be classified as basaloid, basosquamous, and epidermoid. The SGC cytoarchitecture presents either as a nodular or as an infiltrative lesion. Based on immunohistochemistry, the overexpression of ZEB2, BAG3, androgen receptor, and C-erbB-2 oncoprotein is associated with poor prognosis. The tumor is associated with systemic metastasis in 8-14% and death in 10-30%.

Conclusion: Ocular SGC is an aggressive tumor associated with poor prognosis. Early identification and appropriate treatment may help improve the prognosis. New insight into its pathogenesis and the immunohistochemical profile may lead to the development of new effective treatment strategies, along with traditional therapies.

Citing Articles

Case report: A rare case of oral sebaceous carcinoma in the upper lip.

Katib Y, Essatari M Pathol Oncol Res. 2024; 30:1611968.

PMID: 39583063 PMC: 11581884. DOI: 10.3389/pore.2024.1611968.

Clinical Outcomes and Prognostic Factors in Eyelid Malignancy: A 17-Year Retrospective Analysis of Surgical Management and Reconstruction Techniques.

Al Harthi A, Alharthi A, Park J, Yang S Korean J Ophthalmol. 2024; 39(1):14-22.

PMID: 39434573 PMC: 11856049. DOI: 10.3341/kjo.2024.0003.

Molecular landscape of eyelid sebaceous gland carcinoma: A comprehensive review.

Jayaraj P, Ray D, Goel K, Singh A, Kant N, Sen S Indian J Ophthalmol. 2024; 72(10):1393-1403.

PMID: 39331429 PMC: 11573021. DOI: 10.4103/IJO.IJO_167_24.

Clinicopathologic Features of Eyelid Sebaceous Gland Carcinoma Requiring Immunohistochemical Diagnosis.

Yunoki T, Miyakoshi A, Hayashi A Ocul Oncol Pathol. 2024; 10(3):131-138.

PMID: 39224525 PMC: 11368396. DOI: 10.1159/000538537.

Sebaceous carcinoma: an updated review of pathogenesis, diagnosis, and treatment options.

Dowell-Esquivel C, Lee R, DiCaprio 3rd R, Nouri K Arch Dermatol Res. 2023; 316(1):55.

PMID: 38112896 DOI: 10.1007/s00403-023-02747-7.

References

Sinard J . Immunohistochemical distinction of ocular sebaceous carcinoma from basal cell and squamous cell carcinoma. Arch Ophthalmol. 1999; 117(6):776-83. DOI: 10.1001/archopht.117.6.776. View

Rundle P, Shields J, Shields C, Eagle Jr R, Singh A . Sebaceous gland carcinoma of the eyelid seventeen years after irradiation for bilateral retinoblastoma. Eye (Lond). 1999; 13 ( Pt 1):109-10. DOI: 10.1038/eye.1999.20. View

Yen M, Tse D . Sebaceous cell carcinoma of the eyelid and the human immunodeficiency virus. Ophthalmic Plast Reconstr Surg. 2000; 16(3):206-10. DOI: 10.1097/00002341-200005000-00007. View

Cho K, Khang S, Koh J, Chung J, Lee S . Sebaceous carcinoma of the eyelids: frequent expression of c-erbB-2 oncoprotein. J Korean Med Sci. 2000; 15(5):545-50. PMC: 3054683. DOI: 10.3346/jkms.2000.15.5.545. View

Spencer J, Nossa R, Tse D, Sequeira M . Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol. 2001; 44(6):1004-9. DOI: 10.1067/mjd.2001.113692. View

Kivela T, Asko-Seljavaara S, Pihkala U, Hovi L, Heikkonen J . Sebaceous carcinoma of the eyelid associated with retinoblastoma. Ophthalmology. 2001; 108(6):1124-8. DOI: 10.1016/s0161-6420(01)00555-3. View

Chao A, Shields C, Krema H, Shields J . Outcome of patients with periocular sebaceous gland carcinoma with and without conjunctival intraepithelial invasion. Ophthalmology. 2001; 108(10):1877-83. DOI: 10.1016/s0161-6420(01)00719-9. View

Snow S, Larson P, Lucarelli M, Lemke B, Madjar D . Sebaceous carcinoma of the eyelids treated by mohs micrographic surgery: report of nine cases with review of the literature. Dermatol Surg. 2002; 28(7):623-31. DOI: 10.1046/j.1524-4725.2002.01306.x. View

Shields C, Naseripour M, Shields J, Eagle Jr R . Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma. Ophthalmology. 2002; 109(11):2129-33. DOI: 10.1016/s0161-6420(02)01239-3. View

10.

Bailet J, Zimmerman M, Arnstein D, Wollman J, Mickel R . Sebaceous carcinoma of the head and neck. Case report and literature review. Arch Otolaryngol Head Neck Surg. 1992; 118(11):1245-9. DOI: 10.1001/archotol.1992.01880110113020. View

11.

Muqit M, Roberts F, Lee W, Kemp E . Improved survival rates in sebaceous carcinoma of the eyelid. Eye (Lond). 2004; 18(1):49-53. DOI: 10.1038/sj.eye.6700523. View

12.

Arora A, Barlow R, Williamson J, Olver J . Eyelid sebaceous gland carcinoma (SGC) treated with 'slow' Mohs' micrographic surgery. Eye (Lond). 2004; 18(8):854-5. DOI: 10.1038/sj.eye.6701330. View

13.

Shet T, Kelkar G, Juvekar S, Mistry R, Borges A . Masquerade syndrome: sebaceous carcinoma presenting as an unknown primary with pagetoid spread to the nasal cavity. J Laryngol Otol. 2004; 118(4):307-9. DOI: 10.1258/002221504323012094. View

14.

Shields J, Demirci H, Marr B, Eagle Jr R, Shields C . Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology. 2004; 111(12):2151-7. DOI: 10.1016/j.ophtha.2004.07.031. View

15.

Ohara M, Sotozono C, Tsuchihashi Y, Kinoshita S . Ki-67 labeling index as a marker of malignancy in ocular surface neoplasms. Jpn J Ophthalmol. 2004; 48(6):524-9. DOI: 10.1007/s10384-004-0129-0. View

16.

Shields J, Demirci H, Marr B, Eagle Jr R, Shields C . Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol. 2005; 50(2):103-22. DOI: 10.1016/j.survophthal.2004.12.008. View

17.

Mafee M, Karimi A, Shah J, Rapoport M, Ansari S . Anatomy and pathology of the eye: role of MR imaging and CT. Neuroimaging Clin N Am. 2005; 15(1):23-47. DOI: 10.1016/j.nic.2005.02.005. View

18.

Pereira P, Odashiro A, Rodrigues-Reyes A, Correa Z, Souza Filho J, Burnier Jr M . Histopathological review of sebaceous carcinoma of the eyelid. J Cutan Pathol. 2005; 32(7):496-501. DOI: 10.1111/j.0303-6987.2005.00371.x. View

19.

Li B, Li N, Cheng G, Sun X, Xu X, Shi J . Correlation of the expression of telomerase RNA with risk factors for recurrence of sebaceous gland carcinoma. Graefes Arch Clin Exp Ophthalmol. 2005; 244(4):480-4. DOI: 10.1007/s00417-005-0089-1. View

20.

Bouraoui S, Khaddar R, Mokni M, Badri T, Azaiez M, Dhahri A . [Extrapalpebral sebaceous carcinoma]. Ann Dermatol Venereol. 2006; 133(2):165-7. DOI: 10.1016/s0151-9638(06)70870-5. View